BRAF Mutation and CDKN2A deletion define a clinically distinct subgroup of childhood secondary high-grade glioma

• Autor(a) principal: Mistry, Matthew
• Data de Publicação: 2015
• Outros Autores: Zhukova, Nataliya, Merico, Daniele, Rakopoulos, Patricia, Krishnatry, Rahul, Shago, Mary, Stavropoulos, James, Alon, Noa, Pole, Jason D., Ray, Peter N., Navickiene, Vilma, Mangerel, Joshua, Remke, Marc, Buczkowicz, Pawel, Ramaswamy, Vijay, Stucklin, Ana Guerreiro, Li, Martin, Young, Edwin J., Zhang, Cindy, Castelo-Branco, Pedro, Bakry, Doua, Laughlin, Suzanne, Shlien, Adam, Chan, Jennifer, Ligon, Keith L., Rutka, James T., Dirks, Peter B., Taylor, Michael D., Greenberg, Mark, Malkin, David, Huang, Annie, Bouffet, Eric, Hawkins, Cynthia E., Tabori, Uri
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
• Texto Completo: http://hdl.handle.net/10400.1/11546
• topic: Intrinsic pontine glioma; Tert promoter mutations; Central-nervous-system; Pilocytic astrocytomas; Genomic landscape; Histone H3.3; Fusion gene; Tumors; Glioblastoma; Duplication

Purpose To uncover the genetic events leading to transformation of pediatric low-grade glioma (PLGG) to secondary high-grade glioma (sHGG). Patients and Methods We retrospectively identified patients with sHGG from a population-based cohort of 886 patients with PLGG with long clinical follow-up. Exome sequencing and array CGH were performed on available samples followed by detailed genetic analysis of the entire sHGG cohort. Clinical and outcome data of genetically distinct subgroups were obtained. Results sHGG was observed in 2.9% of PLGGs (26 of 886 patients). Patients with sHGG had a high frequency of nonsilent somatic mutations compared with patients with primary pediatric high-grade glioma (HGG; median, 25 mutations per exome; P = .0042). Alterations in chromatin-modifying genes and telomere-maintenance pathways were commonly observed, whereas no sHGG harbored the BRAF-KIAA1549 fusion. The most recurrent alterations were BRAF V600E and CDKN2A deletion in 39% and 57% of sHGGs, respectively. Importantly, all BRAF V600E and 80% of CDKN2A alterations could be traced back to their PLGG counterparts. BRAF V600E distinguished sHGG from primary HGG (P = .0023), whereas BRAF and CDKN2A alterations were less commonly observed in PLGG that did not transform (P < .001 and P < .001 respectively). PLGGs with BRAF mutations had longer latency to transformation than wild-type PLGG (median, 6.65 years [range, 3.5 to 20.3 years] v 1.59 years [range, 0.32 to 15.9 years], respectively; P = .0389). Furthermore, 5-year overall survival was 75% 15% and 29% +/- 12% for children with BRAF mutant and wild-type tumors, respectively (P = .024). Conclusion BRAF V600E mutations and CDKN2A deletions constitute a clinically distinct subtype of sHGG. The prolonged course to transformation for BRAF V600E PLGGs provides an opportunity for surgical interventions, surveillance, and targeted therapies to mitigate the outcome of sHGG. (C) 2015 by American Society of Clinical Oncology